Neuroendocrine Cancer
12
4
4
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 12 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (12)
TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer
DLL3-Targeted PET/CT in Neuroendocrine Carcinoma
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
Ivonescimab in the Treatment of Multiple Advanced Tumors
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Clinical Trial of the Impact of Treatment Consultation Recordings on Cancer Patient Outcomes
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.